Efficacy and safety of traditional Chinese medicine and antiviral antibody therapies for COVID-19: a network meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

SUN Yanjun ¹ , SONG Shuang ¹ , ZHANG Ludan ¹ , LI Nan ¹ , GAO Shengwei ¹ , ZHANG Li ³ , XING Yongfa ³ , MU Wei ³ , WANG Baohe ² ,  HUANG Yuhong ³

1. Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P. R. China;
2. The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300073, P. R. China;
3. The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, P. R. China;

Corresponding author：

HUANG Yuhong, Email: hyh101@126.com

Keywords：

Traditional Chinese medicine; Antiviral antibody; COVID-19; Efficacy; Safety; Network meta-analysis

DOI：

10.7507/1672-2531.202207008

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the efficacy and safety of traditional Chinese medicine (TCM) and antiviral antibody therapy in the treatment of COVID-19. Methods PubMed, EMbase, The Cochrane Library, Web of Science, CNKI, WanFang Data, VIP and SinoMED databases were electronically searched to collect randomized controlled trials (RCTs) on efficacy and safety of traditional Chinese medicine and antiviral antibody therapies for COVID-19 from inception to June 2022. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies; then, network meta-analysis was performed by using Stata 14.0 software. Results A total of 44 RCTs were included. The results of network meta-analysis showed that, for mortality rate, the rank of cumulative probability was: TCM+ standard care (SC) (100%)>convalescent plasma (CP)+SC (42%)>SC (8%). In terms of hospital stay time, the rank of cumulative probability was: TCM+SC (95.5%)>SC (31.4%)>CP+SC (23.2%). In terms of time to viral clearance, the rank of cumulative probability was: TCM+SC (97.4%)>SC (37.4%)>CP+SC (15.2%). In the aspect of mechanical ventilation rate, the rank of cumulative probability was: TCM+SC (98.9%)>CP+SC (42.9%)>SC (8.3%). In the aspect of adverse reactions/events, the rank of cumulative probability was: TCM+SC (99.9%)>SC (47.9%)>CP+SC (2.2%). Conclusion The current evidence shows that TCM combined with SC is the most effective treatment in reducing mortality, shortening hospitalization time and viral negative conversion time, reducing mechanical ventilation rate, and the incidence of adverse reactions/events is low. Due to limited quality and quantity of the included studies, more high quality studies are needed to verify above conclusion.

Citation： SUN Yanjun, SONG Shuang, ZHANG Ludan, LI Nan, GAO Shengwei, ZHANG Li, XING Yongfa, MU Wei, WANG Baohe, HUANG Yuhong. Efficacy and safety of traditional Chinese medicine and antiviral antibody therapies for COVID-19: a network meta-analysis. Chinese Journal of Evidence-Based Medicine, 2022, 22(11): 1309-1318. doi: 10.7507/1672-2531.202207008 Copy

1.	Johns Hopkins University. Coronavirus resource center. Available at: https://coronavirus.jhu.edu/map.html.
2.	National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. Available at: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf.
3.	Zhao Z, Li Y, Zhou L, et al. Prevention and treatment of COVID-19 using Traditional Chinese medicine: a review. Phytomedicine, 2021, 85: 153308.
4.	Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol, 2021, 21(6): 382-393.
5.	Zhang S, Yang Z, Chen ZL, et al. Efficacy and safety of "three Chinese patent medicines and three TCM prescriptions" for COVID-19: a systematic review and network meta-analysis. Evid Based Complement Alternat Med, 2022, 2022: 4654793.
6.	Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ, 2021, 374: n2231.
7.	Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med, 2017, 12(1): 103-111.
8.	国家卫生健康委办公厅, 国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第九版). Available at: http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88/files/ef09aa4070244620b010951b088b8a27.pdf.
9.	The U. S. Food and drug administration. Drugs and non-vaccine biological Products. Available at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs.
10.	European Medicines Agency. COVID-19 treatments. Available at: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-treatments.
11.	Higgins J, Green S. Cochrane handbook for systematic reviews of interventions, version 5.1. 0. The Cochrane Collaboration, 2013.
12.	Ma Q, Xie Y, Wang Z, et al. Efficacy and safety of ReDuNing injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2. J Ethnopharmacol, 2021, 279: 114367.
13.	Zhao J, Yang X, Wang C, et al. Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a. Biomed Pharmacother, 2020, 129: 110436.
14.	Wenguang X, Chanjuan Z, Jixian Z, et al. Randomized controlled study of a diagnosis and treatment plan for moderate coronavirus disease 2019 that integrates Traditional Chinese and Western Medicine. J Tradit Chin Med, 2022, 42(2): 234-241.
15.	Zeng C, Yuan Z, Zhu J, et al. Therapeutic effects of traditional Chinese medicine (Maxingshigan-Weijing Decoction) on COVID-19: An open-label randomized controlled trial. Integr Med Res, 2021, 10(Suppl): 100782.
16.	Zhou S, Feng J, Xie Q, et al. Traditional Chinese medicine shenhuang granule in patients with severe/critical COVID-19: A randomized controlled multicenter trial. Phytomedicine, 2021, 89: 153612.
17.	Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine, 2021, 93: 153775.
18.	Wang JB, Wang ZX, Jing J, et al. Exploring an integrative therapy for treating COVID-19: a randomized controlled trial. Chin J Integr Med, 2020, 26(9): 648-655.
19.	Zhang L, Wu L, Xu X, et al. Efficacy and safety of lianhua qingke tablets in the treatment of mild and common-type COVID-19: a randomized, controlled, multicenter clinical study. Evid Based Complement Alternat Med, 2022, 2022: 8733598.
20.	Zhang XY, Lv L, Zhou YL, et al. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: a multicenter, prospective, open-label and randomized controlled trial. Phytother Res, 2021, 35(8): 4401-4410.
21.	Xu X, Zhang J, Zheng W, et al. Efficacy and safety of Reduning injection in the treatment of COVID-19: a randomized, multicenter clinical study. Ann Palliat Med, 2021, 10(5): 5146-5155.
22.	Liu J, Yang W, Liu Y, et al. Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): a single-center, open-label, randomized controlled trial. Phytomedicine, 2021, 91: 153671.
23.	Zhao C, Li L, Yang W, et al. Chinese medicine formula Huashibaidu granule early treatment for mild COVID-19 patients: an unblinded, cluster-randomized clinical trial. Front Med (Lausanne), 2021, 8: 696976.
24.	叶玲, 赵红佳, 徐顺贵, 等. 加味升降散治疗普通型COVID-19的临床效果研究. 中外医学研究, 2021, 19(28): 9-13.
25.	平祥华, 徐海龄, 付东方, 等. 加味玉屏风散联合西药治疗COVID-19的临床观察. 基层医学论坛, 2021, 25(2): 149-151.
26.	段璨, 夏文广, 郑婵娟, 等. 金花清感颗粒联合西医常规治疗方案治疗轻型新型冠状病毒肺炎的临床观察. 中医杂志, 2020, 61(17): 1473-1477.
27.	张又莉, 雷亮, 徐勇, 等. 金银花口服液治疗新型冠状病毒肺炎80例临床疗效分析. 中国药业, 2020, 29(9): 23-26.
28.	刘武, 苏晓勇, 廖祥莉, 等. 抗病毒药物联合中药治疗轻型新型冠状病毒肺炎的效果分析. 当代医药论丛, 2021, 19(2): 159-160.
29.	陈超武, 李晓良, 刘亚峰, 等. 连花清瘟胶囊治疗新型冠状病毒肺炎临床研究. 中西医结合研究, 2021, 13(1): 1-4.
30.	余平, 李叶子, 万少兵, 等. 连花清瘟颗粒联合阿比多尔治疗轻度新型冠状病毒肺炎的疗效观察. 中国药学杂志, 2020, 55(12): 1042-1045.
31.	王月, 陈立, 郑玲, 等. 清肺排毒汤联合常规治疗对新冠肺炎患者的临床疗效. 中成药, 2021, 43(3): 656-659.
32.	王林, 徐梦, 王瑜, 等. 生脉散合参苓白术散加减治疗普通型2019冠状病毒病临床研究. 中华中医药杂志, 2020, 35(8): 4268-4271.
33.	颜成果, 闪海霞, 裴旭东, 等. 疏风解毒胶囊联合α-干扰素和阿比多尔治疗普通型新型冠状病毒肺炎的疗效和安全性分析. 广州中医药大学学报, 2022, 39(3): 475-480.
34.	陈良忠, 刘辉, 肖国龙. 血必净注射液在新冠肺炎治疗中的疗效及对CRP的影响. 中国处方药, 2020, 18(10): 110-111.
35.	郑子洲, 白志刚, 李常杰, 等. 中医辨证治疗新型冠状病毒肺炎效果观察. 交通医学, 2020, 34(2): 117-118.
36.	廖国荣. 自拟中药汤剂在新型冠状肺炎患者中的应用效果及安全性研究. 国际感染病学(电子版), 2020, 9(2): 353.
37.	Kirenga B, Byakika-Kibwika P, Muttamba W, et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ Open Respir Res, 2021, 8(1): e001017.
38.	Gharbharan A, Jordans CCE, GeurtsvanKessel C, et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Commun, 2021, 12(1): 3189.
39.	Devos T, Van Thillo Q, Compernolle V, et al. Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. Eur Respir J, 2022, 59(2): 2101724.
40.	AlQahtani M, Abdulrahman A, Almadani A, et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Sci Rep, 2021, 11(1): 9927.
41.	Bar KJ, Shaw PA, Choi GH, et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest, 2021, 131(24): e155114.
42.	Körper S, Weiss M, Zickler D, et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest, 2021, 131(20): e152264.
43.	Pouladzadeh M, Safdarian M, Eshghi P, et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Intern Emerg Med, 2021, 16(8): 2181-2191.
44.	Menichetti F, Popoli P, Puopolo M, et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Netw Open, 2021, 4(11): e2136246.
45.	Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA, 2020, 324(5): 460-470.
46.	Avendaño-Solá C, Ramos-Martínez A, Muñez-Rubio E, et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. J Clin Invest, 2021, 131(20): e152740.
47.	Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase Ⅱ multicentre randomised controlled trial (PLACID Trial). BMJ, 2020, 371: m3939.
48.	Bajpai M, Maheshwari A, Dogra V, et al. Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-Ⅱ trial). BMJ Open, 2022, 12(4): e055189.
49.	Bégin P, Callum J, Jamula E, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med, 2021, 27(11): 2012-2024.
50.	Sekine L, Arns B, Fabro BR, et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. Eur Respir J, 2022, 59(2): 2101471.
51.	Holm K, Lundgren MN, Kjeldsen-Kragh J, et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden. BMC Res Notes, 2021, 14(1): 440.
52.	林菲菲, 黄建平, 杨军, 等. 宣肺清热方辅助治疗普通型新型冠状病毒肺炎临床研究. 浙江中西医结合杂志, 2020, 30(12): 977-981.
53.	李亚冬, 张文静. 新冠肺炎中西医治疗方案临床效果评价. 光明中医, 2020, 35(9): 1273-1275.
54.	艾香英, 罗纯, 林路平, 等. 广州市新型冠状病毒肺炎中西医结合治疗疗效. 中国热带医学, 2020, 20(8): 746-750.
55.	傅晓霞, 林路平, 谭行华. 中西医结合治疗新型冠状病毒肺炎37例临床研究. 中药新药与临床药理, 2020, 31(5): 600-604.
56.	Wu SS, Zhou QX, Zeng XY, et al. Comparative effectiveness and safety of 32 pharmacological interventions recommended by guidelines for coronavirus disease 2019: a systematic review and network meta-analysis combining 66 trials. Chin Med J (Engl), 2021, 134(16): 1920-1929.
57.	Yu R, Zhang S, Zhao D, et al. A systematic review of outcomes in COVID-19 patients treated with western medicine in combination with traditional Chinese medicine versus western medicine alone. Expert Rev Mol Med, 2022, 24: e5.
58.	Li L, Xie H, Wang L, et al. The efficacy and safety of combined chinese herbal medicine and western medicine therapy for COVID-19: a systematic review and meta-analysis. Chin Med, 2022, 17(1): 77.
59.	Jiang F, Xu N, Zhou Y, et al. Contribution of traditional Chinese medicine combined with conventional western medicine treatment for the novel coronavirus disease (COVID-19), current evidence with systematic review and meta-analysis. Phytother Res, 2021, 35(11): 5992-6009.
60.	Wang H, Xu B, Zhang Y, et al. Efficacy and safety of traditional Chinese medicine in coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Front Pharmacol, 2021, 12: 609213.
61.	Farhangnia P, Dehrouyeh S, Safdarian AR, et al. Recent advances in passive immunotherapies for COVID-19: the evidence-based approaches and clinical trials. Int Immunopharmacol, 2022, 109: 108786.
62.	Chan W, He B, Wang X, et al. Pandemic COVID-19: Current status and challenges of antiviral therapies. Genes Dis, 2020, 7(4): 502-519.
63.	Piechotta V, Chai KL, Valk SJ, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev, 2020, (7): CD013600.
64.	Agarwal A, Rochwerg B, Lamontagne F, et al. A living WHO guideline on drugs for covid-19. BMJ, 2020, 370: m3379.
65.	Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med, 2021, 384(7): 619-629.
66.	Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early convalescent plasma for high-risk outpatients with COVID-19. N Engl J Med, 2021, 385(21): 1951-1960.

1. Johns Hopkins University. Coronavirus resource center. Available at: https://coronavirus.jhu.edu/map.html.
2. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. Available at: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf.
3. Zhao Z, Li Y, Zhou L, et al. Prevention and treatment of COVID-19 using Traditional Chinese medicine: a review. Phytomedicine, 2021, 85: 153308.
4. Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol, 2021, 21(6): 382-393.
5. Zhang S, Yang Z, Chen ZL, et al. Efficacy and safety of "three Chinese patent medicines and three TCM prescriptions" for COVID-19: a systematic review and network meta-analysis. Evid Based Complement Alternat Med, 2022, 2022: 4654793.
6. Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ, 2021, 374: n2231.
7. Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med, 2017, 12(1): 103-111.
8. 国家卫生健康委办公厅, 国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第九版). Available at: http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88/files/ef09aa4070244620b010951b088b8a27.pdf.
9. The U. S. Food and drug administration. Drugs and non-vaccine biological Products. Available at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs.
10. European Medicines Agency. COVID-19 treatments. Available at: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-treatments.
11. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions, version 5.1. 0. The Cochrane Collaboration, 2013.
12. Ma Q, Xie Y, Wang Z, et al. Efficacy and safety of ReDuNing injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2. J Ethnopharmacol, 2021, 279: 114367.
13. Zhao J, Yang X, Wang C, et al. Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a. Biomed Pharmacother, 2020, 129: 110436.
14. Wenguang X, Chanjuan Z, Jixian Z, et al. Randomized controlled study of a diagnosis and treatment plan for moderate coronavirus disease 2019 that integrates Traditional Chinese and Western Medicine. J Tradit Chin Med, 2022, 42(2): 234-241.
15. Zeng C, Yuan Z, Zhu J, et al. Therapeutic effects of traditional Chinese medicine (Maxingshigan-Weijing Decoction) on COVID-19: An open-label randomized controlled trial. Integr Med Res, 2021, 10(Suppl): 100782.
16. Zhou S, Feng J, Xie Q, et al. Traditional Chinese medicine shenhuang granule in patients with severe/critical COVID-19: A randomized controlled multicenter trial. Phytomedicine, 2021, 89: 153612.
17. Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine, 2021, 93: 153775.
18. Wang JB, Wang ZX, Jing J, et al. Exploring an integrative therapy for treating COVID-19: a randomized controlled trial. Chin J Integr Med, 2020, 26(9): 648-655.
19. Zhang L, Wu L, Xu X, et al. Efficacy and safety of lianhua qingke tablets in the treatment of mild and common-type COVID-19: a randomized, controlled, multicenter clinical study. Evid Based Complement Alternat Med, 2022, 2022: 8733598.
20. Zhang XY, Lv L, Zhou YL, et al. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: a multicenter, prospective, open-label and randomized controlled trial. Phytother Res, 2021, 35(8): 4401-4410.
21. Xu X, Zhang J, Zheng W, et al. Efficacy and safety of Reduning injection in the treatment of COVID-19: a randomized, multicenter clinical study. Ann Palliat Med, 2021, 10(5): 5146-5155.
22. Liu J, Yang W, Liu Y, et al. Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): a single-center, open-label, randomized controlled trial. Phytomedicine, 2021, 91: 153671.
23. Zhao C, Li L, Yang W, et al. Chinese medicine formula Huashibaidu granule early treatment for mild COVID-19 patients: an unblinded, cluster-randomized clinical trial. Front Med (Lausanne), 2021, 8: 696976.
24. 叶玲, 赵红佳, 徐顺贵, 等. 加味升降散治疗普通型COVID-19的临床效果研究. 中外医学研究, 2021, 19(28): 9-13.
25. 平祥华, 徐海龄, 付东方, 等. 加味玉屏风散联合西药治疗COVID-19的临床观察. 基层医学论坛, 2021, 25(2): 149-151.
26. 段璨, 夏文广, 郑婵娟, 等. 金花清感颗粒联合西医常规治疗方案治疗轻型新型冠状病毒肺炎的临床观察. 中医杂志, 2020, 61(17): 1473-1477.
27. 张又莉, 雷亮, 徐勇, 等. 金银花口服液治疗新型冠状病毒肺炎80例临床疗效分析. 中国药业, 2020, 29(9): 23-26.
28. 刘武, 苏晓勇, 廖祥莉, 等. 抗病毒药物联合中药治疗轻型新型冠状病毒肺炎的效果分析. 当代医药论丛, 2021, 19(2): 159-160.
29. 陈超武, 李晓良, 刘亚峰, 等. 连花清瘟胶囊治疗新型冠状病毒肺炎临床研究. 中西医结合研究, 2021, 13(1): 1-4.
30. 余平, 李叶子, 万少兵, 等. 连花清瘟颗粒联合阿比多尔治疗轻度新型冠状病毒肺炎的疗效观察. 中国药学杂志, 2020, 55(12): 1042-1045.
31. 王月, 陈立, 郑玲, 等. 清肺排毒汤联合常规治疗对新冠肺炎患者的临床疗效. 中成药, 2021, 43(3): 656-659.
32. 王林, 徐梦, 王瑜, 等. 生脉散合参苓白术散加减治疗普通型2019冠状病毒病临床研究. 中华中医药杂志, 2020, 35(8): 4268-4271.
33. 颜成果, 闪海霞, 裴旭东, 等. 疏风解毒胶囊联合α-干扰素和阿比多尔治疗普通型新型冠状病毒肺炎的疗效和安全性分析. 广州中医药大学学报, 2022, 39(3): 475-480.
34. 陈良忠, 刘辉, 肖国龙. 血必净注射液在新冠肺炎治疗中的疗效及对CRP的影响. 中国处方药, 2020, 18(10): 110-111.
35. 郑子洲, 白志刚, 李常杰, 等. 中医辨证治疗新型冠状病毒肺炎效果观察. 交通医学, 2020, 34(2): 117-118.
36. 廖国荣. 自拟中药汤剂在新型冠状肺炎患者中的应用效果及安全性研究. 国际感染病学(电子版), 2020, 9(2): 353.
37. Kirenga B, Byakika-Kibwika P, Muttamba W, et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ Open Respir Res, 2021, 8(1): e001017.
38. Gharbharan A, Jordans CCE, GeurtsvanKessel C, et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Commun, 2021, 12(1): 3189.
39. Devos T, Van Thillo Q, Compernolle V, et al. Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. Eur Respir J, 2022, 59(2): 2101724.
40. AlQahtani M, Abdulrahman A, Almadani A, et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Sci Rep, 2021, 11(1): 9927.
41. Bar KJ, Shaw PA, Choi GH, et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest, 2021, 131(24): e155114.
42. Körper S, Weiss M, Zickler D, et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest, 2021, 131(20): e152264.
43. Pouladzadeh M, Safdarian M, Eshghi P, et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Intern Emerg Med, 2021, 16(8): 2181-2191.
44. Menichetti F, Popoli P, Puopolo M, et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Netw Open, 2021, 4(11): e2136246.
45. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA, 2020, 324(5): 460-470.
46. Avendaño-Solá C, Ramos-Martínez A, Muñez-Rubio E, et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. J Clin Invest, 2021, 131(20): e152740.
47. Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase Ⅱ multicentre randomised controlled trial (PLACID Trial). BMJ, 2020, 371: m3939.
48. Bajpai M, Maheshwari A, Dogra V, et al. Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-Ⅱ trial). BMJ Open, 2022, 12(4): e055189.
49. Bégin P, Callum J, Jamula E, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med, 2021, 27(11): 2012-2024.
50. Sekine L, Arns B, Fabro BR, et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. Eur Respir J, 2022, 59(2): 2101471.
51. Holm K, Lundgren MN, Kjeldsen-Kragh J, et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden. BMC Res Notes, 2021, 14(1): 440.
52. 林菲菲, 黄建平, 杨军, 等. 宣肺清热方辅助治疗普通型新型冠状病毒肺炎临床研究. 浙江中西医结合杂志, 2020, 30(12): 977-981.
53. 李亚冬, 张文静. 新冠肺炎中西医治疗方案临床效果评价. 光明中医, 2020, 35(9): 1273-1275.
54. 艾香英, 罗纯, 林路平, 等. 广州市新型冠状病毒肺炎中西医结合治疗疗效. 中国热带医学, 2020, 20(8): 746-750.
55. 傅晓霞, 林路平, 谭行华. 中西医结合治疗新型冠状病毒肺炎37例临床研究. 中药新药与临床药理, 2020, 31(5): 600-604.
56. Wu SS, Zhou QX, Zeng XY, et al. Comparative effectiveness and safety of 32 pharmacological interventions recommended by guidelines for coronavirus disease 2019: a systematic review and network meta-analysis combining 66 trials. Chin Med J (Engl), 2021, 134(16): 1920-1929.
57. Yu R, Zhang S, Zhao D, et al. A systematic review of outcomes in COVID-19 patients treated with western medicine in combination with traditional Chinese medicine versus western medicine alone. Expert Rev Mol Med, 2022, 24: e5.
58. Li L, Xie H, Wang L, et al. The efficacy and safety of combined chinese herbal medicine and western medicine therapy for COVID-19: a systematic review and meta-analysis. Chin Med, 2022, 17(1): 77.
59. Jiang F, Xu N, Zhou Y, et al. Contribution of traditional Chinese medicine combined with conventional western medicine treatment for the novel coronavirus disease (COVID-19), current evidence with systematic review and meta-analysis. Phytother Res, 2021, 35(11): 5992-6009.
60. Wang H, Xu B, Zhang Y, et al. Efficacy and safety of traditional Chinese medicine in coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Front Pharmacol, 2021, 12: 609213.
61. Farhangnia P, Dehrouyeh S, Safdarian AR, et al. Recent advances in passive immunotherapies for COVID-19: the evidence-based approaches and clinical trials. Int Immunopharmacol, 2022, 109: 108786.
62. Chan W, He B, Wang X, et al. Pandemic COVID-19: Current status and challenges of antiviral therapies. Genes Dis, 2020, 7(4): 502-519.
63. Piechotta V, Chai KL, Valk SJ, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev, 2020, (7): CD013600.
64. Agarwal A, Rochwerg B, Lamontagne F, et al. A living WHO guideline on drugs for covid-19. BMJ, 2020, 370: m3379.
65. Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med, 2021, 384(7): 619-629.
66. Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early convalescent plasma for high-risk outpatients with COVID-19. N Engl J Med, 2021, 385(21): 1951-1960.

Chinese Journal of Evidence-Based Medicine

Efficacy and safety of traditional Chinese medicine and antiviral antibody therapies for COVID-19: a network meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content